X |
Filing Date |
Trade Date |
Ticker |
Company Name | Insider Name | Title |
Trade Type |
Price |
Qty |
Owned |
ΔOwn |
Value |
1d |
1w |
1m |
6m |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
2026-11-04 | PMN | Promis Neurosciences Inc. | Williams Eugene | Dir | P - Purchase | $3.43 | +26,500 | 40,213 | +193% | +$90,895 | ||||||
| M | 2026-11-03 | GRCE | Grace Therapeutics, Inc. | Opaleye Management Inc. | 10% | P - Purchase | $1.79 | +18,442 | 3,054,853 | +1% | +$33,019 | |||||
2026-11-03 | VSTM | Verastem, Inc. | Paterson Dan | Pres, CEO | S - Sale | $9.60 | -1,299 | 651,413 | 0% | -$12,470 | ||||||
2026-11-03 | JAZZ | Jazz Pharmaceuticals Plc | Gala Renee D | Pres, CEO | S - Sale | $225.37 | -1,000 | 140,394 | -1% | -$225,370 | ||||||
| M | 2026-11-03 | BOLD | Boundless Bio, Inc. | Tang Kevin | 10% | P - Purchase | $2.40 | +11,162 | 3,033,618 | 0% | +$26,789 | |||||
2026-11-03 | ROIV | Roivant Sciences Ltd. | Venker Eric | Pres, Immunovant CEO | S - Sale | $36.31 | -200,000 | 999,154 | -17% | -$7,262,000 | ||||||
2026-11-05 | LAB | Standard Biotools Inc. | Carey Thomas D. | Dir | P - Purchase | $0.63 | +75,000 | 419,456 | +22% | +$46,898 | ||||||
2026-11-04 | LYEL | Lyell Immunopharma, Inc. | Arch Venture Partners Ix, LLC | 10% | P - Purchase | $10.77 | +2,321,262 | 5,568,424 | +71% | +$24,999,992 | ||||||
2026-11-04 | LYEL | Lyell Immunopharma, Inc. | Arch Venture Fund Xiii, L.P. | 10% | P - Purchase | $10.77 | +2,321,262 | 5,568,424 | +71% | +$24,999,992 | ||||||
2026-11-04 | UTHR | United Therapeutics Corp | Rothblatt Martine A | CHAIRPERSON, CEO | S - Sale | $611.06 | -1,723 | 668,728 | 0% | -$1,052,854 | ||||||
| D | 2026-11-04 | UTHR | United Therapeutics Corp | Rothblatt Martine A | CHAIRPERSON, CEO | S - Sale+OE | $599.64 | -7,777 | 670,451 | -1% | -$4,663,396 | |||||
2026-11-03 | GNLX | Genelux Corp | Cappello Joseph | Chief Technical Officer | S - Sale | $2.04 | -668 | 317,812 | 0% | -$1,363 | ||||||
2026-11-03 | GNLX | Genelux Corp | Zindrick Thomas | Pres, CEO | S - Sale | $2.05 | -3,089 | 1,423,338 | 0% | -$6,317 | ||||||
2026-11-03 | GNLX | Genelux Corp | Yu Yong | Chief Scientific Officer | S - Sale | $2.01 | -668 | 258,020 | 0% | -$1,344 | ||||||
| D | 2026-11-05 | UTHR | United Therapeutics Corp | Mahon Paul A | EVP, GC | S - Sale+OE | $598.67 | -8,300 | 45,172 | -16% | -$4,968,933 | |||||
| M | 2026-11-03 | VNDA | Vanda Pharmaceuticals Inc. | Duncan Charles Cliff | Dir | P - Purchase | $3.81 | +10,000 | 108,701 | +10% | +$38,094 | |||||
2026-11-04 | MBX | Mbx Biosciences, Inc. | Azoulay Salomon | Chief Medical Officer | S - Sale | $53.96 | -373 | 14,026 | -3% | -$20,127 | ||||||
2026-11-05 | OPK | Opko Health, Inc. | Paganelli John A | Dir | S - Sale | $1.81 | -13,601 | 389,914 | -3% | -$24,577 | ||||||
| D | 2026-11-03 | REGN | Regeneron Pharmaceuticals, Inc. | Zoghbi Huda Y | Dir | S - Sale+OE | $970.46 | -7,439 | 1,703 | -81% | -$7,219,274 | |||||
2026-11-03 | IRD | Opus Genetics, Inc. | Magrath George | CEO | S - Sale | $3.90 | -28,258 | 2,010,636 | -1% | -$110,184 | ||||||
2026-11-04 | TAK | Takeda Pharmaceutical Co Ltd | Platford Giles Richard | Pres, IBU | S - Sale | $20.90 | -55,617 | 270,253 | -17% | -$1,162,395 | ||||||
| D | 2026-11-04 | MIRM | Mirum Pharmaceuticals, Inc. | Peetz Christopher | CEO | S - Sale+OE | $90.00 | -20,000 | 394,137 | -5% | -$1,800,000 | |||||
| D | 2026-11-02 | MNPR | Monopar Therapeutics | Anderson Raymond | Dir | S - Sale+OE | $68.35 | -3,142 | 5,373 | -37% | -$214,746 | |||||
| DM | 2026-11-02 | MNPR | Monopar Therapeutics | Tsuchimoto Kim R | Dir | S - Sale+OE | $70.92 | -4,090 | 11,486 | -26% | -$290,062 | |||||
| D | 2026-11-02 | TNGX | Tango Therapeutics, Inc. | Crystal Adam | Pres, R, D | S - Sale+OE | $22.42 | -5,000 | 115,743 | -4% | -$112,108 | |||||
2026-11-02 | TNGX | Tango Therapeutics, Inc. | Newcomb Jessica | Principal Accounting Officer | S - Sale | $22.42 | -7,031 | 52,090 | -12% | -$157,661 | ||||||
| DM | 2026-11-02 | CORT | Corcept Therapeutics Inc | Maduck Sean | See Remarks | S - Sale+OE | $81.85 | -25,000 | 129,593 | -16% | -$2,046,351 | |||||
| D | 2026-11-02 | CORT | Corcept Therapeutics Inc | Vieira Roberto Wandenkolk | Pres, Oncology | S - Sale+OE | $80.89 | -8,333 | 3,946 | -68% | -$674,069 | |||||
| D | 2026-11-02 | ASPE | Aspen Neuroscience, Inc. | Thompson Peter A. | Dir, 10% | P - Purchase | $15.00 | +1,000,000 | 3,589,132 | +39% | +$15,000,000 | |||||
| D | 2026-11-02 | ASPE | Aspen Neuroscience, Inc. | Orbimed Advisors LLC | Dir, 10% | P - Purchase | $15.00 | +1,000,000 | 3,589,132 | +39% | +$15,000,000 | |||||
| DM | 2026-11-02 | ARQT | Arcutis Biotherapeutics, Inc. | Matsuda Masaru | EVP, GC | S - Sale+OE | $34.24 | -41,219 | 111,289 | -27% | -$1,411,513 | |||||
2026-11-02 | ARQT | Arcutis Biotherapeutics, Inc. | Burnett Patrick | EVP, Chief Medical Officer | S - Sale | $31.86 | -943 | 116,649 | -1% | -$30,047 | ||||||
2026-11-02 | ARQT | Arcutis Biotherapeutics, Inc. | Watanabe Todd | See Remarks | S - Sale | $31.86 | -4,377 | 945,960 | 0% | -$139,466 | ||||||
2026-11-02 | JAZZ | Jazz Pharmaceuticals Plc | Cozadd Bruce C | Dir | S - Sale | $215.84 | -6,000 | 339,875 | -2% | -$1,295,040 | ||||||
2026-11-02 | TAK | Takeda Pharmaceutical Co Ltd | Bitetti Teresa Marie | Pres, OBU | S - Sale | $20.89 | -46,609 | 214,501 | -18% | -$973,662 | ||||||
2026-11-04 | NRIX | Nurix Therapeutics, Inc. | Van Houte Hans | CFO | S - Sale | $15.63 | -4,769 | 42,745 | -10% | -$74,562 | ||||||
| DM | 2026-11-02 | NRIX | Nurix Therapeutics, Inc. | Ring Christine | GC | S - Sale+OE | $25.84 | -16,715 | 4,406 | -79% | -$431,904 | |||||
2026-11-02 | XERS | Xeris Biopharma Holdings, Inc. | Pieper Steven | See Remarks | S - Sale | $10.23 | -5,000 | 1,346,053 | 0% | -$51,174 | ||||||
2026-11-02 | XERS | Xeris Biopharma Holdings, Inc. | Hecht Beth | See Remarks | S - Sale | $10.23 | -25,000 | 1,086,130 | -2% | -$255,828 | ||||||
2026-11-02 | XERS | Xeris Biopharma Holdings, Inc. | McCulloch Kevin | See Remarks | S - Sale | $10.23 | -15,000 | 1,609,208 | -1% | -$153,488 | ||||||
2026-11-02 | ALMS | Alumis Inc. | Schroer John R. | CFO | S - Sale | $6.52 | -794 | 23,924 | -3% | -$5,177 | ||||||
2026-11-02 | ALMS | Alumis Inc. | Pangali Sanam | GC | S - Sale | $6.52 | -332 | 9,415 | -3% | -$2,165 | ||||||
| D | 2026-11-03 | UTHR | United Therapeutics Corp | Rothblatt Martine A | CHAIRPERSON, CEO | S - Sale+OE | $601.92 | -9,500 | 668,728 | -1% | -$5,718,264 | |||||
2026-11-02 | ALMS | Alumis Inc. | Hardiman Roy C. | Chief Business, Strategy Ofcr | S - Sale | $6.52 | -652 | 213,511 | 0% | -$4,251 | ||||||
2026-11-02 | ALMS | Alumis Inc. | Goldstein David M | Chief Scientific Officer | S - Sale | $6.52 | -629 | 247,572 | 0% | -$4,101 | ||||||
| D | 2026-11-02 | LGND | Ligand Pharmaceuticals Inc | Reardon Andrew | CLO, Secretary | S - Sale+OE | $313.22 | -5,000 | 31,854 | -14% | -$1,566,094 | |||||
2026-11-02 | ALMS | Alumis Inc. | Drappa Jorn | Chief Medical Officer | S - Sale | $6.52 | -593 | 56,299 | -1% | -$3,866 | ||||||
2026-11-02 | ALMS | Alumis Inc. | Bradley Mark Christopher | Chief Development Officer | S - Sale | $6.52 | -623 | 87,962 | -1% | -$4,062 | ||||||
| D | 2026-11-02 | REGN | Regeneron Pharmaceuticals, Inc. | Sing George L | Dir | S - Sale+OE | $964.38 | -21,129 | 27,297 | -44% | -$20,376,358 | |||||
| D | 2026-11-02 | REGN | Regeneron Pharmaceuticals, Inc. | Poon Christine A | Dir | S - Sale+OE | $969.09 | -7,830 | 5,219 | -60% | -$7,587,958 | |||||
2026-11-02 | STOK | Stoke Therapeutics, Inc. | Ticho Barry | Chief Medical Officer | S - Sale | $26.40 | -7,195 | 11,864 | -38% | -$189,912 | ||||||
2026-10-29 | GENB | Generate Biomedicines, Inc. | Arnold Frances | Dir | S - Sale | $16.19 | -11,409 | 452,535 | -2% | -$184,733 | ||||||
| D | 2026-11-02 | REGN | Regeneron Pharmaceuticals, Inc. | Larosa Joseph J | EVP GC, Secret | S - Sale+OE | $965.49 | -4,466 | 44,726 | -9% | -$4,311,890 | |||||
2026-11-03 | SPTX | Seaport Therapeutics, Inc. | Torres Denice | Dir | P - Purchase | $19.87 | +5,000 | 18,406 | +37% | +$99,325 | ||||||
| M | 2026-10-30 | LGND | Ligand Pharmaceuticals Inc | Aryeh Jason | Dir | S - Sale | $320.30 | -2,111 | 116,758 | -2% | -$676,158 | |||||
| DM | 2026-10-30 | KNSA | Kiniksa Pharmaceuticals International, Plc | Patel Sanj K | COB, CEO | S - Sale+OE | $92.92 | -402,494 | 966,006 | -29% | -$37,400,327 | |||||
2026-11-03 | ALKS | Alkermes Plc. | Gaffin David Joseph | EVP, CLO, Alkermes, Inc. | S - Sale | $46.17 | -2,035 | 219,353 | -1% | -$93,956 | ||||||
| D | 2026-11-02 | KNSA | Kiniksa Pharmaceuticals International, Plc | Ragosa Mark | CFO | S - Sale+OE | $92.16 | -36,783 | 20,854 | -64% | -$3,389,975 | |||||
| DM | 2026-10-30 | KNSA | Kiniksa Pharmaceuticals International, Plc | Paolini John F. | CHIEF MEDICAL OFFICER | S - Sale+OE | $93.09 | -96,000 | 69,922 | -58% | -$8,937,067 | |||||
| DM | 2026-10-30 | KNSA | Kiniksa Pharmaceuticals International, Plc | Moat Ross | COO | S - Sale+OE | $92.93 | -103,585 | 10,294 | -91% | -$9,625,790 | |||||
| D | 2026-10-30 | KNSA | Kiniksa Pharmaceuticals International, Plc | Megna Michael R | CHIEF ACCOUNTING OFFICER | S - Sale+OE | $94.43 | -36,260 | 12,697 | -74% | -$3,424,091 | |||||
2026-11-02 | ASMB | Assembly Biosciences, Inc. | Bjorkquist Jeanette M | PFO, PAO | S - Sale | $19.62 | -727 | 17,673 | -4% | -$14,261 | ||||||
2026-11-02 | ASMB | Assembly Biosciences, Inc. | White Nicole S | Chief Manufacturing Officer | S - Sale | $19.62 | -2,593 | 59,257 | -4% | -$50,864 | ||||||
| D | 2026-11-03 | CYTK | Cytokinetics Inc | Malik Fady Ibraham | EVP Research, Development | S - Sale+OE | $62.93 | -3,500 | 153,902 | -2% | -$220,255 | |||||
2026-11-02 | ASMB | Assembly Biosciences, Inc. | Gaggar Anuj | Chief Medical Officer | S - Sale | $19.62 | -2,593 | 53,800 | -5% | -$50,864 | ||||||
| D | 2026-11-02 | UTHR | United Therapeutics Corp | Rothblatt Martine A | CHAIRPERSON, CEO | S - Sale+OE | $596.23 | -9,500 | 668,728 | -1% | -$5,664,136 | |||||
2026-11-02 | ASMB | Assembly Biosciences, Inc. | Okazaki Jason A | CEO, Pres | S - Sale | $19.62 | -6,202 | 195,532 | -3% | -$121,658 | ||||||
| D | 2026-10-30 | REGN | Regeneron Pharmaceuticals, Inc. | Guarini Kathryn | Dir | S - Sale+OE | $900.00 | -400 | 603 | -40% | -$360,000 | |||||
2026-10-30 | BBIO | Bridgebio Pharma, Inc. | Apuli Maricel | Chief Accounting Officer | S - Sale | $72.85 | -2,000 | 120,687 | -2% | -$145,700 | ||||||
| E | 2026-11-02 | LLY | Eli Lilly & Co | Hakim Anat | EVP, GC, Secretary | S - Sale | $0.28 | -5,000 | 45,562 | -10% | -$1,403 | |||||
| D | 2026-10-30 | REGN | Regeneron Pharmaceuticals, Inc. | Brown Michael S | Dir | S - Sale+OE | $875.00 | -1,929 | 12,865 | -13% | -$1,687,875 | |||||
2026-10-30 | REGN | Regeneron Pharmaceuticals, Inc. | McCourt Marion | EVP Commercial | S - Sale | $869.43 | -1,132 | 11,090 | -9% | -$984,195 | ||||||
2026-10-30 | PMN | Promis Neurosciences Inc. | Williams Eugene | Dir | P - Purchase | $3.99 | +1,316 | 13,713 | +11% | +$5,251 | ||||||
2026-11-02 | PMN | Promis Neurosciences Inc. | Cashman Neil | Chief Scientific Officer | P - Purchase | $3.86 | +10,000 | 19,318 | +107% | +$38,600 | ||||||
| D | 2026-11-02 | ASPE | Aspen Neuroscience, Inc. | Arch Venture Fund X, L.P. | 10% | P - Purchase | $15.00 | +1,333,333 | 2,361,074 | +130% | +$19,999,995 | |||||
2026-11-02 | ASPE | Aspen Neuroscience, Inc. | Arch Venture Partners Xiv, L.P. | 10% | P - Purchase | $15.00 | +1,200,000 | 1,200,000 | New | +$18,000,000 | ||||||
| D | 2026-10-30 | NRIX | Nurix Therapeutics, Inc. | Van Houte Hans | CFO | S - Sale+OE | $26.28 | -2,834 | 47,514 | -6% | -$74,475 | |||||
| D | 2026-10-30 | NRIX | Nurix Therapeutics, Inc. | Ring Christine | GC | S - Sale+OE | $26.28 | -3,957 | 15,335 | -21% | -$103,986 | |||||
| DM | 2026-10-30 | NRIX | Nurix Therapeutics, Inc. | Hansen Gwenn | Chief Scientific Officer | S - Sale+OE | $26.42 | -5,409 | 123,452 | -4% | -$142,900 | |||||
| D | 2026-11-02 | CYTK | Cytokinetics Inc | Blum Robert I | Pres, CEO | S - Sale+OE | $62.81 | -7,500 | 282,710 | -3% | -$471,075 | |||||
| D | 2026-11-02 | ORKA | Oruka Therapeutics, Inc. | Klein Lawrence Otto | CEO | S - Sale+OE | $95.61 | -25,000 | 923,128 | -3% | -$2,390,125 | |||||
| D | 2026-10-30 | UTHR | United Therapeutics Corp | Rothblatt Martine A | CHAIRPERSON, CEO | S - Sale+OE | $600.09 | -9,500 | 668,728 | -1% | -$5,700,856 | |||||
2026-10-29 | CRBP | Corbus Pharmaceuticals Holdings, Inc. | Cormorant Asset Management, LP | Former 10% Owner | S - Sale | $4.10 | -425,000 | 1,919,971 | -18% | -$1,742,755 | ||||||
2026-10-30 | ANIX | Anixa Biosciences Inc | Kumar Amit | CEO | P - Purchase | $3.17 | +5,000 | 685,000 | +1% | +$15,850 | ||||||
2026-10-30 | ACAD | Acadia Pharmaceuticals Inc | Schneyer Mark C. | EVP, CFO | S - Sale | $20.88 | -3,321 | 71,322 | -4% | -$69,342 | ||||||
2026-10-28 | RAPP | Rapport Therapeutics, Inc. | Healy James | Dir | P - Purchase | $21.00 | +969,480 | 2,873,888 | +51% | +$20,359,080 | ||||||
| D | 2026-10-29 | SNDX | Syndax Pharmaceuticals Inc | Podlesak Dennis | Dir | S - Sale+OE | $14.21 | -8,000 | 239,763 | -3% | -$113,716 | |||||
2026-10-28 | ROIV | Roivant Sciences Ltd. | Venker Eric | Pres, Immunovant CEO | S - Sale | $36.59 | -200,000 | 1,199,154 | -14% | -$7,318,000 | ||||||
2026-10-29 | ANIP | Ani Pharmaceuticals Inc | Carey Stephen P. | SVP, CFO | S - Sale | $72.87 | -2,850 | 166,143 | -2% | -$207,680 | ||||||
| D | 2026-10-29 | UTHR | United Therapeutics Corp | Rothblatt Martine A | CHAIRPERSON, CEO | S - Sale+OE | $594.78 | -9,500 | 668,728 | -1% | -$5,650,415 | |||||
| M | 2026-10-29 | OTLC | Oncotelic Therapeutics, Inc. | Trieu Vuong | COB, CEO, 10% | P - Purchase | $0.02 | +1,356,990 | 118,089,232 | +1% | +$23,537 | |||||
2026-10-27 | BOLD | Boundless Bio, Inc. | Tang Kevin | 10% | P - Purchase | $2.40 | +10,707 | 3,022,456 | 0% | +$25,697 | ||||||
| D | 2026-10-27 | ONC | Beone Medicines Ltd. | Wang Xiaodong | Chair, Scientific Advisory Brd | S - Sale+OE | $362.97 | -31,028 | 9,566,326 | 0% | -$11,262,131 | |||||
| M | 2026-10-27 | VRXA | Veraxa Biotech AG - Post De-Spac | Gruninger Marc | Dir | P - Purchase | $1.00 | +10,000 | 10,000 | New | +$9,983 | |||||
| D | 2026-10-28 | UTHR | United Therapeutics Corp | Rothblatt Martine A | CHAIRPERSON, CEO | S - Sale+OE | $585.49 | -9,500 | 668,728 | -1% | -$5,562,190 | |||||
| D | 2026-10-28 | ACTU | Actuate Therapeutics, Inc. | Schmitt Daniel M | Pres, CEO, Dir | P - Purchase | $0.36 | +140,844 | 1,073,300 | +15% | +$50,000 | |||||
2026-10-27 | RLYB | Rallybio Corp | Lieber Jonathan I | CFO | S - Sale | $16.04 | -599 | 15,551 | -4% | -$9,608 | ||||||
2026-10-26 | LQDA | Liquidia Corp | Boyle Dana | Chief Accounting Officer | S - Sale | $43.19 | -1,581 | 164,028 | -1% | -$68,283 | ||||||
| D | 2026-10-27 | UTHR | United Therapeutics Corp | Rothblatt Martine A | CHAIRPERSON, CEO | S - Sale+OE | $587.73 | -9,500 | 668,728 | -1% | -$5,583,418 | |||||
2026-10-26 | LQDA | Liquidia Corp | Adair Jason | Chief Business Officer | S - Sale | $43.19 | -688 | 177,269 | 0% | -$29,715 |
| A | Amended filing |
| D | Derivative transaction in filing (usually option exercise) |
| E | Error detected in filing |
| M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
| S - Sale | Sale of securities on an exchange or to another person |
| S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
| F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
| P - Purchase | Purchase of securities on an exchange or from another person |